Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation
Tóm tắt
Từ khóa
Tài liệu tham khảo
SS Dave, , Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351, 2159–2169 (2004).
AM Glas, , Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 25, 390–398 (2007).
S Kiaii, , Follicular lymphoma cells induce changes in T-cell gene expression and function: Potential impact on survival and risk of transformation. J Clin Oncol 31, 2654–2661 (2013).
R Kridel, LH Sehn, RD Gascoyne, Pathogenesis of follicular lymphoma. J Clin Invest 122, 3424–3431 (2012).
MR Green, AA Alizadeh, Common progenitor cells in mature B-cell malignancies: Implications for therapy. Curr Opin Hematol 21, 333–340 (2014).
AD Zelenetz, , Enhanced detection of the t(14;18) translocation in malignant lymphoma using pulsed-field gel electrophoresis. Blood 78, 1552–1560 (1991).
S Roulland, , Follicular lymphoma-like B cells in healthy individuals: A novel intermediate step in early lymphomagenesis. J Exp Med 203, 2425–2431 (2006).
S Roulland, , t(14;18) Translocation: A predictive blood biomarker for follicular lymphoma. J Clin Oncol 32, 1347–1355 (2014).
E Mamessier, , Nature and importance of follicular lymphoma precursors. Haematologica 99, 802–810 (2014).
J Tellier, , Human t(14;18)positive germinal center B cells: A new step in follicular lymphoma pathogenesis? Blood 123, 3462–3465 (2014).
L Pasqualucci, , Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471, 189–195 (2011).
MR Green, , Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 121, 1604–1611 (2013).
J Okosun, , Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 46, 176–181 (2014).
L Pasqualucci, , Genetics of follicular lymphoma transformation. Cell Rep 6, 1–11
H Li, , Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood 123, 1487–1498 (2014).
IH Su, A Tarakhovsky, Epigenetic control of B cell differentiation. Semin Immunol 17, 167–172 (2005).
TB Tomasi, WJ Magner, AN Khan, Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother 55, 1159–1184 (2006).
W Béguelin, , EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23, 677–692 (2013).
RK Thomas, , High-throughput oncogene mutation profiling in human cancer. Nat Genet 39, 347–351 (2007).
R Salari, , Inference of tumor phylogenies with improved somatic mutation discovery. J Comput Biol 20, 933–944 (2013).
CG Mullighan, , CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471, 235–239 (2011).
MR Green, , Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin’s lymphoma. Genes Chromosomes Cancer 50, 313–326 (2011).
E Oricchio, , The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell 147, 554–564 (2011).
PJ van den Elsen, MC van Eggermond, RJ Wierda, Epigenetic control in immune function. Adv Exp Med Biol 711, 36–49 (2011).
LH Glimcher, CJ Kara, Sequences and factors: A guide to MHC class-II transcription. Annu Rev Immunol 10, 13–49 (1992).
RD Morin, , Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42, 181–185 (2010).
RD Morin, , Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298–303 (2011).
Y Kikushige, , Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 20, 246–259 (2011).
S Chung, , Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Sci Transl Med 238, 238ra71 (2014).
MT McCabe, , EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108–112 (2012).
A Kretsovali, , Involvement of CREB binding protein in expression of major histocompatibility complex class II genes via interaction with the class II transactivator. Mol Cell Biol 18, 6777–6783 (1998).
JD Fontes, S Kanazawa, D Jean, BM Peterlin, Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes. Mol Cell Biol 19, 941–947 (1999).
GW Beresford, JM Boss, CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter. Nat Immunol 2, 652–657 (2001).
JD Brody, , In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: A phase I/II study. J Clin Oncol 28, 4324–4332 (2010).
S Afshar-Sterle, , Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas. Nat Med 20, 283–290 (2014).
EM Janssen, , CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421, 852–856 (2003).
DJ Shedlock, H Shen, Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300, 337–339 (2003).
LM Rimsza, , Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood 107, 1101–1107 (2006).
LM Rimsza, , Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: A follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 103, 4251–4258 (2004).
C Steidl, , MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471, 377–381 (2011).
OK Weinberg, , “Minor” BCL2 breakpoints in follicular lymphoma: Frequency and correlation with grade and disease presentation in 236 cases. J Mol Diagn 9, 530–537 (2007).
K Cibulskis, , Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31, 213–219 (2013).
DC Koboldt, , VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 22, 568–576 (2012).
A McKenna, , The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20, 1297–1303 (2010).
SB Ng, , Targeted capture and massively parallel sequencing of 12 human exomes. Nature 461, 272–276 (2009).
DE Newburger, , Genome evolution during progression to breast cancer. Genome Res 23, 1097–1108 (2013).
IB Schäfer, , Crystal structure of the archaeal A1Ao ATP synthase subunit B from Methanosarcina mazei Gö1: Implications of nucleotide-binding differences in the major A1Ao subunits A and B. J Mol Biol 358, 725–740 (2006).
M Delvecchio, J Gaucher, C Aguilar-Gurrieri, E Ortega, D Panne, Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation. Nat Struct Mol Biol 20, 1040–1046 (2013).
U Pieper, , ModBase, a database of annotated comparative protein structure models and associated resources. Nucleic Acids Res 42, D336–D346 (2014).
F Kiefer, K Arnold, M Künzli, L Bordoli, T Schwede, The SWISS-MODEL Repository and associated resources. Nucleic Acids Res 37, D387–D392 (2009).
Jr G Dennis, , DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol 4, 3 (2003).
A Subramanian, H Kuehn, J Gould, P Tamayo, JP Mesirov, GSEA-P: A desktop application for gene set enrichment analysis. Bioinformatics 23, 3251–3253 (2007).